Syndesi Therapeutics Company
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
Technology:
NeuroTech
Industry:
Biotechnology, Health Care, Science and Engineering
Headquarters:
Louvain-la-neuve, Vlaams-Brabant, Belgium
Founded Date:
2018-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
5
Total Funding:
€17M
Estimated Revenue:
Less than $1M
Last Funding Type:
Series A
Register and Claim Ownership